🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,441
Drugs tracked
4,077

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

43 results for “X4” Clear

  1. ASCs (Cx401, company code)

    Takeda Pharmaceuticals International AG

    Anal Fistula

    phase 3 small molecule completed

    1 trial

  2. BCX4161

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  3. DTX401

    Ultragenyx UK Limited

    Glycogen Storage Disease Type IA

    phase 3 gene therapy completed

    1 trial

  4. Mavorixafor

    X4 Pharmaceuticals, Inc

    Neutropenia

    phase 3 small molecule active

    2 trials

  5. Mavorixafor

    X4 Pharmaceuticals, Inc

    WHIM Syndrome

    phase 3 small molecule active

    1 trial

  6. Mavorixafor, Mavorixafor Placebo Capsules

    X4 Pharmaceuticals, Inc

    Neutropenias

    phase 3 small molecule active

    1 trial

  7. Mavorixafor, Placebo to Test IMP

    X4 Pharmaceuticals, Inc

    WHIM Syndrome

    phase 3 small molecule active

    1 trial

  8. PLACEBO SOTAGLIFLOZIN, SOTAGLIFLOZIN

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  9. Prednisolon STADA® 5 mg Tabletten, Prednisolone placebo hard capsule, 10 mg, Prednisolone Placebo hard capsule, 5mg, Prednisolon STADA® 10 mg Tabletten, Pariglasgene brecaparvovec, Normal Saline

    Lacuna Pharma Pty Ltd

    Glycogen Storage Disease Type Ia (GSDIa)

    phase 3 small molecule active

    1 trial

  10. Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE

    Roche Products Pty Ltd

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    phase 3 small molecule active

    1 trial

  11. 75 mg LX4211

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  12. ADX48621

    Addex Therapeutics

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  13. ARO-DUX4 for Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Facio-Scapulo-Humeral Dystrophy

    phase 2 small molecule active

    1 trial

  14. DTX401

    Ultragenyx UK Limited

    GSD1

    phase 2 gene therapy completed

    1 trial

  15. INBRX-106 - Hexavalent OX40 agonist antibody

    Inhibrx Biosciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  16. IRX4204

    IO Biotech

    Psoriasis

    phase 2 small molecule on hold

    1 trial

  17. LX4211 Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  18. PEMBROLIZUMAB, OLAPARIB, OLAPARIB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency

    phase 2 small molecule active

    1 trial

  19. SODIUM CHLORIDE, ARO-DUX4

    Sarepta Therapeutics

    Facioscapulohumeral muscular dystrophy (FSHD)

    phase 2 small molecule active

    1 trial

  20. X4P-001

    X4 Pharmaceuticals, Inc

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule completed

    2 trials

  21. X4P-001

    X4 Pharmaceuticals, Inc

    WHIM Syndrome

    phase 2 small molecule completed

    1 trial

  22. 300 mg LX4211 (150 mg tablets)

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  23. 400 mg LX4211

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  24. ADX48621

    Addex Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources